Uploaded December 2025 | Updated September 2026, 2 weeks ago
GLP-1 medications are changing obesity treatment — but what happens when you stop using them? And what’s next in the pipeline? Today, we’re breaking down two major stories shaking up the obesity drug space.
First, we turn to Eli Lilly’s new obesity drug retatrutide — a triple-agonist that’s shocking researchers with Phase 3 results showing nearly 29% total body weight loss and significant improvements in osteoarthritis knee pain. But there’s a catch: side effects and intolerance led to major dropout rates, and some patients even quit because they lost “too much” weight. We’ll break down how retatrutide works, why the results outperform Zepbound and Mounjaro, and what this means for the future of GLP-1 treatment.
Whether you’re using a GLP-1, considering one, or simply curious about the science, this video gives you the full picture — clear, evidence-based, and easy to understand.
Second, new clinical data on Mounjaro (tirzepatide) shows what really happens after stopping treatment. In a large post-discontinuation study, most patients experienced significant weight regain within a year — along with the reversal of key health benefits like improved blood pressure, cholesterol, blood sugar levels, and waist circumference. We’ll explain what tirzepatide does inside the body, how the SURMOUNT-4 trial was structured, why 82% of participants regained at least 25% of their weight, and what experts say about GLP-1 medications as long-term therapy.
💬 Drop a comment:
Have you used Mounjaro or another GLP-1? Planning to stay on it? Would you take a drug that delivers this much weight loss even with side effects? Share your experience.
👍 Like the video
📌 Subscribe for weekly content
🔔 Turn on alerts so you don’t miss new uploadsDo you like this personality?
IViM Telehealth (Affiliate Link): ivimhealth.sjv.io/o4XVPE
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#zepbound #mounjaro #glp1 #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #TheWeeklyShot #HealthyMENtality #glp1news
GLP-1 medications are changing obesity treatment — but what happens when you stop using them? And what’s next in the pipeline? Today, we’re breaking down two major stories shaking up the obesity drug space.
First, we turn to Eli Lilly’s new obesity drug retatrutide — a triple-agonist that’s shocking researchers with Phase 3 results showing nearly 29% total body weight loss and significant improvements in osteoarthritis knee pain. But there’s a catch: side effects and intolerance led to major dropout rates, and some patients even quit because they lost “too much” weight. We’ll break down how retatrutide works, why the results outperform Zepbound and Mounjaro, and what this means for the future of GLP-1 treatment.
Whether you’re using a GLP-1, considering one, or simply curious about the science, this video gives you the full picture — clear, evidence-based, and easy to understand.
Second, new clinical data on Mounjaro (tirzepatide) shows what really happens after stopping treatment. In a large post-discontinuation study, most patients experienced significant weight regain within a year — along with the reversal of key health benefits like improved blood pressure, cholesterol, blood sugar levels, and waist circumference. We’ll explain what tirzepatide does inside the body, how the SURMOUNT-4 trial was structured, why 82% of participants regained at least 25% of their weight, and what experts say about GLP-1 medications as long-term therapy.
💬 Drop a comment:
Have you used Mounjaro or another GLP-1? Planning to stay on it? Would you take a drug that delivers this much weight loss even with side effects? Share your experience.
👍 Like the video
📌 Subscribe for weekly content
🔔 Turn on alerts so you don’t miss new uploadsDo you like this personality?
IViM Telehealth (Affiliate Link): ivimhealth.sjv.io/o4XVPE
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#zepbound #mounjaro #glp1 #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #TheWeeklyShot #HealthyMENtality #glp1news
